Immunocore Holdings (IMCR) Invested Capital (2019 - 2025)
Immunocore Holdings (IMCR) has disclosed Invested Capital for 7 consecutive years, with $381.0 million as the latest value for Q4 2025.
- Quarterly Invested Capital rose 5.63% to $381.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $381.0 million through Dec 2025, up 5.63% year-over-year, with the annual reading at $381.0 million for FY2025, 5.63% up from the prior year.
- Invested Capital hit $381.0 million in Q4 2025 for Immunocore Holdings, down from $396.6 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $396.6 million in Q3 2025 to a low of $325.1 million in Q4 2021.
- Historically, Invested Capital has averaged $362.2 million across 5 years, with a median of $360.1 million in 2024.
- Biggest five-year swings in Invested Capital: skyrocketed 167.61% in 2021 and later dropped 2.2% in 2024.
- Year by year, Invested Capital stood at $325.1 million in 2021, then rose by 0.57% to $327.0 million in 2022, then rose by 12.81% to $368.8 million in 2023, then decreased by 2.2% to $360.7 million in 2024, then rose by 5.63% to $381.0 million in 2025.
- Business Quant data shows Invested Capital for IMCR at $381.0 million in Q4 2025, $396.6 million in Q3 2025, and $388.5 million in Q2 2025.